prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
prascend 1mg tablets for horses
boehringer ingelheim vetmedica gmbh - pergolide mesilate 1.31 mg - tablet - horses non food - pergolide
azilect
teva israel ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
azilect
teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
azilect
teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
comtan
novartis israel ltd - entacapone - film coated tablets - entacapone 200 mg - entacapone - entacapone - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.